Brief: Tempest Receives FDA Study May Proceed For Pivotal Phase 3 Trial Of Amezalpat Combination Therapy For The Treatment Of First-Line Hepatocellular Carcinoma
12/11/2024 13:21
Nov 12 (Reuters) - Tempest Therapeutics Inc TPST.O :
* TEMPEST RECEIVES FDA STUDY MAY PROCEED FOR PIVOTAL PHASE 3
TRIAL
OF AMEZALPAT COMBINATION THERAPY FOR THE TREATMENT OF FIRST-LINE
HEPATOCELLULAR CARCINOMA
* TEMPEST RECEIVES FDA STUDY MAY PROCEED FOR PIVOTAL PHASE 3
TRIAL
OF AMEZALPAT COMBINATION THERAPY FOR THE TREATMENT OF FIRST-LINE
HEPATOCELLULAR CARCINOMA
* TEMPEST THERAPEUTICS INC - PHASE 3 STUDY EXPECTED TO START
IN Q1
2025
Source text: ID:nGNX6Kh4vb
Further company coverage: TPST.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tempest Therapeutics
See all newsBrief: Tempest Therapeutics - Justin Trojanowski To Resign As Principal Financial Officer And Principal Accounting Officer Effective Sept 1 - SEC Filing
Tempest Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tempest Therapeutics - Enters $50 Million Common Stock Purchase Agreement With Lincoln Park
Tempest Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Tempest Announces Development Collaboration With Senlang Biotechnology For TPST-4003, A CD7-Targeted Next-Generation In Vivo CAR-T